Tocagen Stock Price, News & Analysis (NASDAQ:TOCA)

$12.39 +0.05 (+0.41 %)
(As of 02/19/2018 04:00 PM ET)
Previous Close$12.39
Today's Range$12.27 - $12.80
52-Week Range$8.60 - $17.95
VolumeN/A
Average Volume142,290 shs
Market Capitalization$245.44 million
P/E Ratio-6.20
Dividend YieldN/A
BetaN/A

About Tocagen (NASDAQ:TOCA)

Tocagen logoTocagen Inc. (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells. Its lead product candidates are vocimagene amiretrorepvec (Toca 511) and flucytosine extended release (Toca FC). Toca 511 is an investigational injectable retroviral replicating vector (RRV) that encodes a prodrug activator enzyme, cytosine deaminase (CD). Toca FC is an investigational extended-release version of 5-fluorocytosine (5-FC), a prodrug that is inactive as an anti-cancer drug. As of February, 2017, Tocagen has completed enrollment of the Phase II portion with 187 patients.

Receive TOCA News and Ratings via Email

Sign-up to receive the latest news and ratings for TOCA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:TOCA
CUSIPN/A
Phone+1-858-4128400

Debt

Debt-to-Equity Ratio0.07%
Current Ratio6.03%
Quick Ratio6.03%

Price-To-Earnings

Trailing P/E Ratio-6.195
Forward P/E Ratio-4.66
P/E GrowthN/A

Sales & Book Value

Annual Sales$40,000.00
Price / Sales6,136.15
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($2.00)
Net Income$-33,470,000.00
Net Margins-89,078.05%
Return on EquityN/A
Return on Assets-51.70%

Miscellaneous

Employees61
Outstanding Shares19,810,000

Tocagen (NASDAQ:TOCA) Frequently Asked Questions

What is Tocagen's stock symbol?

Tocagen trades on the NASDAQ under the ticker symbol "TOCA."

How were Tocagen's earnings last quarter?

Tocagen Inc (NASDAQ:TOCA) announced its quarterly earnings data on Wednesday, November, 8th. The company reported ($0.50) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.48) by $0.02. The firm earned $0.01 million during the quarter, compared to analyst estimates of $0.01 million. View Tocagen's Earnings History.

When will Tocagen make its next earnings announcement?

Tocagen is scheduled to release their next quarterly earnings announcement on Wednesday, February, 21st 2018. View Earnings Estimates for Tocagen.

Where is Tocagen's stock going? Where will Tocagen's stock price be in 2018?

2 equities research analysts have issued 12-month price objectives for Tocagen's stock. Their predictions range from $19.00 to $28.00. On average, they expect Tocagen's stock price to reach $23.67 in the next twelve months. View Analyst Ratings for Tocagen.

Who are some of Tocagen's key competitors?

Who are Tocagen's key executives?

Tocagen's management team includes the folowing people:

  • Faheem Hasnain, Independent Chairman of the Board (Age 58)
  • Martin J. Duvall, Chief Executive Officer, Director (Age 54)
  • Mark G. Foletta CPA, Chief Financial Officer, Executive Vice President (Age 55)
  • Harry E. Gruber M.D., President - Science and Innovation, Director (Age 64)
  • Dennis N. Berman, Executive Vice President - Corporate Development (Age 65)
  • Douglas Jolly Ph.D., Executive Vice President - Research and Pharmaceutical Development (Age 69)
  • Asha Das M.D., Senior Vice President, Chief Medical Officer (Age 52)
  • Thomas E. Darcy, Director (Age 66)
  • Franklin M. Berger, Independent Director (Age 67)
  • Lori A. Kunkel M.D., Independent Director (Age 59)

When did Tocagen IPO?

(TOCA) raised $80 million in an IPO on Thursday, April 13th 2017. The company issued 7,300,000 shares at $10.00-$12.00 per share. Leerink Partners, Evercore ISI and Stifel acted as the underwriters for the IPO.

Who owns Tocagen stock?

Tocagen's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.40%), BVF Inc. IL (2.81%), Pure Financial Advisors Inc. (0.65%), Lake Street Advisors Group LLC (0.51%), Artal Group S.A. (0.50%) and Geode Capital Management LLC (0.46%). Company insiders that own Tocagen stock include Asha Das, Harry E Gruber, Mark G Foletta and Paul Schimmel. View Institutional Ownership Trends for Tocagen.

Who sold Tocagen stock? Who is selling Tocagen stock?

Tocagen's stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Victory Capital Management Inc. and Doheny Asset Management CA. View Insider Buying and Selling for Tocagen.

Who bought Tocagen stock? Who is buying Tocagen stock?

Tocagen's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Pure Financial Advisors Inc., Lake Street Advisors Group LLC, Artal Group S.A., BBR Partners LLC, Blankinship & Foster LLC, Deutsche Bank AG and Bank of New York Mellon Corp. Company insiders that have bought Tocagen stock in the last two years include Asha Das, Harry E Gruber, Mark G Foletta and Paul Schimmel. View Insider Buying and Selling for Tocagen.

How do I buy Tocagen stock?

Shares of Tocagen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Tocagen's stock price today?

One share of Tocagen stock can currently be purchased for approximately $12.39.

How big of a company is Tocagen?

Tocagen has a market capitalization of $245.44 million and generates $40,000.00 in revenue each year. The company earns $-33,470,000.00 in net income (profit) each year or ($2.00) on an earnings per share basis. Tocagen employs 61 workers across the globe.

How can I contact Tocagen?

Tocagen's mailing address is 3030 Bunker Hill St Ste 230, SAN DIEGO, CA 92109-5757, United States. The company can be reached via phone at +1-858-4128400 or via email at [email protected]


MarketBeat Community Rating for Tocagen (TOCA)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  67 (Vote Outperform)
Underperform Votes:  85 (Vote Underperform)
Total Votes:  152
MarketBeat's community ratings are surveys of what our community members think about Tocagen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Tocagen (NASDAQ:TOCA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.672.67
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $23.67$23.67$23.67$23.67
Price Target Upside: 112.07% upside112.07% upside112.07% upside112.07% upside

Tocagen (NASDAQ:TOCA) Consensus Price Target History

Price Target History for Tocagen (NASDAQ:TOCA)

Tocagen (NASDAQ:TOCA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/25/2017Stifel NicolausReiterated RatingBuy$24.00LowView Rating Details
5/15/2017Leerink SwannInitiated CoverageMkt Perform$19.00MediumView Rating Details
5/9/2017Evercore ISIReiterated RatingOutperform$28.00LowView Rating Details
(Data available from 2/19/2016 forward)

Earnings

Tocagen (NASDAQ:TOCA) Earnings History and Estimates Chart

Earnings by Quarter for Tocagen (NASDAQ:TOCA)

Tocagen (NASDAQ TOCA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/21/2018        
11/8/2017Q3 2017($0.48)($0.50)$0.01 million$0.01 millionViewN/AView Earnings Details
8/9/2017Q2($0.52)($0.56)$0.01 million$0.01 millionViewN/AView Earnings Details
5/23/2017Q1 2017($2.70)($4.11)$0.01 million$0.01 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Tocagen (NASDAQ:TOCA) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.66 EPS
Next Year EPS Consensus Estimate: $-2.93 EPS

Dividends

Dividend History for Tocagen (NASDAQ:TOCA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Tocagen (NASDAQ TOCA) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 39.25%
Insider Trades by Quarter for Tocagen (NASDAQ:TOCA)
Institutional Ownership by Quarter for Tocagen (NASDAQ:TOCA)

Tocagen (NASDAQ TOCA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/19/2017Asha DasSVPBuy2,500$10.00$25,000.002,500View SEC Filing  
4/19/2017Harry E GruberInsiderBuy25,000$10.00$250,000.00View SEC Filing  
4/19/2017Mark G FolettaCFOBuy5,000$10.00$50,000.005,000View SEC Filing  
4/19/2017Paul SchimmelDirectorBuy10,000$10.00$100,000.0023,464View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Tocagen (NASDAQ TOCA) News Headlines

Source:
DateHeadline
Tocagen (TOCA) Presents At Leerink Partners 7th Annual Global Healthcare Conference - SlideshowTocagen (TOCA) Presents At Leerink Partners 7th Annual Global Healthcare Conference - Slideshow
seekingalpha.com - February 15 at 4:25 PM
Tocagen (TOCA) vs. Aduro BioTech (ADRO) Financial AnalysisTocagen (TOCA) vs. Aduro BioTech (ADRO) Financial Analysis
www.americanbankingnews.com - February 10 at 1:14 AM
Tocagen to Present at Leerink Partners 7th Annual Global Healthcare ConferenceTocagen to Present at Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 7 at 9:03 AM
Tocagen (TOCA) Upgraded to "Sell" at ValuEngineTocagen (TOCA) Upgraded to "Sell" at ValuEngine
www.americanbankingnews.com - February 4 at 11:46 AM
Tocagen Inc (TOCA) Given Consensus Rating of "Hold" by BrokeragesTocagen Inc (TOCA) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 2 at 1:34 AM
BidaskClub Downgrades Tocagen (TOCA) to HoldBidaskClub Downgrades Tocagen (TOCA) to Hold
www.americanbankingnews.com - January 31 at 11:02 AM
Brokerages Anticipate Tocagen Inc (TOCA) to Post ($0.53) EPSBrokerages Anticipate Tocagen Inc (TOCA) to Post ($0.53) EPS
www.americanbankingnews.com - January 27 at 9:14 PM
 Tocagen Inc (TOCA) Given $23.67 Average Price Target by Analysts Tocagen Inc (TOCA) Given $23.67 Average Price Target by Analysts
www.americanbankingnews.com - January 20 at 9:34 PM
Tocagen Inc (TOCA) Short Interest UpdateTocagen Inc (TOCA) Short Interest Update
www.americanbankingnews.com - January 14 at 2:34 AM
Tocagen (TOCA) Upgraded to "Hold" by Zacks Investment ResearchTocagen (TOCA) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - January 11 at 1:46 PM
Contrasting Tocagen (TOCA) & The CompetitionContrasting Tocagen (TOCA) & The Competition
www.americanbankingnews.com - January 6 at 5:02 AM
 Tocagen Inc (TOCA) Receives Consensus Recommendation of "Buy" from Analysts Tocagen Inc (TOCA) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 5 at 5:30 AM
Head-To-Head Survey: Tocagen (TOCA) & Its PeersHead-To-Head Survey: Tocagen (TOCA) & Its Peers
www.americanbankingnews.com - December 28 at 3:21 AM
Tocagen (TOCA) vs. Its Rivals Financial ContrastTocagen (TOCA) vs. Its Rivals Financial Contrast
www.americanbankingnews.com - December 28 at 12:16 AM
Analyzing Tocagen (TOCA) and The CompetitionAnalyzing Tocagen (TOCA) and The Competition
www.americanbankingnews.com - December 26 at 1:10 AM
 Brokerages Set $23.67 Target Price for Tocagen Inc (TOCA) Brokerages Set $23.67 Target Price for Tocagen Inc (TOCA)
www.americanbankingnews.com - December 17 at 7:26 PM
Reviewing Rigel Pharmaceuticals (RIGL) & Tocagen (TOCA)Reviewing Rigel Pharmaceuticals (RIGL) & Tocagen (TOCA)
www.americanbankingnews.com - December 16 at 5:12 PM
Tocagen (TOCA) & Zafgen (ZFGN) Financial ReviewTocagen (TOCA) & Zafgen (ZFGN) Financial Review
www.americanbankingnews.com - December 9 at 9:36 AM
 Analysts Set $23.67 Target Price for Tocagen Inc (TOCA) Analysts Set $23.67 Target Price for Tocagen Inc (TOCA)
www.americanbankingnews.com - December 2 at 9:52 AM
Tocagen Inc (TOCA) Downgraded by Zacks Investment Research to SellTocagen Inc (TOCA) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - November 25 at 10:28 AM
Tocagen Announces Time Change for Presentation at Evercore ISI Biopharma Catalyst/Deep Dive ConferenceTocagen Announces Time Change for Presentation at Evercore ISI Biopharma Catalyst/Deep Dive Conference
finance.yahoo.com - November 22 at 12:15 PM
Zacks: Brokerages Set $23.67 Price Target for Tocagen Inc (TOCA)Zacks: Brokerages Set $23.67 Price Target for Tocagen Inc (TOCA)
www.americanbankingnews.com - November 15 at 5:06 AM
Tocagen to Present at Two Investor Conferences in NovemberTocagen to Present at Two Investor Conferences in November
finance.yahoo.com - November 10 at 9:19 AM
Tocagen Inc (TOCA) Issues Quarterly  Earnings ResultsTocagen Inc (TOCA) Issues Quarterly Earnings Results
www.americanbankingnews.com - November 9 at 7:48 PM
Tocagen Reports Third Quarter 2017 Financial and Business ResultsTocagen Reports Third Quarter 2017 Financial and Business Results
finance.yahoo.com - November 9 at 8:18 AM
Tocagen to Present Updated Clinical and Preclinical Data at Three Scientific ConferencesTocagen to Present Updated Clinical and Preclinical Data at Three Scientific Conferences
finance.yahoo.com - November 9 at 8:18 AM
Are Tocagen Inc’s (TOCA) Interest Costs Too High?Are Tocagen Inc’s (TOCA) Interest Costs Too High?
finance.yahoo.com - November 5 at 7:36 AM
Tocagen to Report Third Quarter 2017 Financial Results on Wednesday, November 8Tocagen to Report Third Quarter 2017 Financial Results on Wednesday, November 8
finance.yahoo.com - November 2 at 9:55 AM
TOCAGEN INC (TOCA) Scheduled to Post Quarterly Earnings on WednesdayTOCAGEN INC (TOCA) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - November 2 at 9:53 AM
Financial Review: Applied Genetic Technologies Corporation (AGTC) versus Tocagen (TOCA)Financial Review: Applied Genetic Technologies Corporation (AGTC) versus Tocagen (TOCA)
www.americanbankingnews.com - October 31 at 11:10 PM
Tocagen (TOCA) to Accelerate Toca 511 and Toca FC Development into Pivotal Phase 3 TrialTocagen (TOCA) to Accelerate Toca 511 and Toca FC Development into Pivotal Phase 3 Trial
www.streetinsider.com - October 27 at 4:32 PM
Tocagen Presents Updated Durable Complete Response Data from Phase 1 Trial of Toca 511 & Toca FC in Recurrent High-Grade GliomaTocagen Presents Updated Durable Complete Response Data from Phase 1 Trial of Toca 511 & Toca FC in Recurrent High-Grade Glioma
finance.yahoo.com - October 27 at 4:32 PM
Tocagen to Accelerate Toca 511 & Toca FC Development into Pivotal Phase 3 TrialTocagen to Accelerate Toca 511 & Toca FC Development into Pivotal Phase 3 Trial
finance.yahoo.com - October 27 at 6:58 AM
Tocagen to Present Updated Durable Response Data from Phase 1 Trial of Toca 511 & Toca FC in Recurrent Brain Cancer at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsTocagen to Present Updated Durable Response Data from Phase 1 Trial of Toca 511 & Toca FC in Recurrent Brain Cancer at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
finance.yahoo.com - October 17 at 8:11 AM
Tocagen Inc (TOCA) Upgraded by Zacks Investment Research to "Hold"Tocagen Inc (TOCA) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - October 11 at 1:32 PM
Tocagen Enters Oversold Territory (TOCA)Tocagen Enters Oversold Territory (TOCA)
www.thestreet.com - October 7 at 9:13 AM
Tocagen Incs Lock-Up Period Will Expire  on October 10th (NASDAQ:TOCA)Tocagen Inc's Lock-Up Period Will Expire on October 10th (NASDAQ:TOCA)
www.americanbankingnews.com - October 3 at 1:18 AM
 Tocagen Inc (TOCA) Receives Consensus Rating of "Buy" from Brokerages Tocagen Inc (TOCA) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - September 18 at 2:48 PM
 Tocagen Inc (TOCA) Given $23.67 Consensus Target Price by Analysts Tocagen Inc (TOCA) Given $23.67 Consensus Target Price by Analysts
www.americanbankingnews.com - September 14 at 4:36 AM
Tocagen Inc (NASDAQ:TOCA) Releases Quarterly  Earnings Results, Misses Expectations By $0.04 EPSTocagen Inc (NASDAQ:TOCA) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS
www.americanbankingnews.com - August 10 at 10:24 PM
Tocagen Reports Second Quarter 2017 Financial and Business ResultsTocagen Reports Second Quarter 2017 Financial and Business Results
finance.yahoo.com - August 10 at 8:52 AM
 Tocagen Inc (NASDAQ:TOCA) Given $23.67 Consensus Target Price by Analysts Tocagen Inc (NASDAQ:TOCA) Given $23.67 Consensus Target Price by Analysts
www.americanbankingnews.com - August 8 at 10:40 PM
 Tocagen Inc (NASDAQ:TOCA) Receives Consensus Recommendation of "Buy" from Brokerages Tocagen Inc (NASDAQ:TOCA) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - August 5 at 4:36 PM
Tocagen Inc (NASDAQ:TOCA) to Release Quarterly Earnings on WednesdayTocagen Inc (NASDAQ:TOCA) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - August 3 at 12:06 PM
Tocagen to Report Second Quarter 2017 Financial Results on Wednesday, August 9Tocagen to Report Second Quarter 2017 Financial Results on Wednesday, August 9
finance.yahoo.com - August 3 at 8:00 AM
Short Interest in Tocagen Inc (NASDAQ:TOCA) Decreases By 47.8%Short Interest in Tocagen Inc (NASDAQ:TOCA) Decreases By 47.8%
www.americanbankingnews.com - July 29 at 7:14 AM
Tocagen Inc (NASDAQ:TOCA) Earns "Buy" Rating from Stifel NicolausTocagen Inc (NASDAQ:TOCA) Earns "Buy" Rating from Stifel Nicolaus
www.americanbankingnews.com - July 25 at 9:32 PM
BRIEF-Tocagen receives PRIME designation for Toca 511BRIEF-Tocagen receives PRIME designation for Toca 511
www.reuters.com - July 25 at 7:43 AM
Tocagen Receives European Medicines Agency Priority Medicines (PRIME) Designation for Toca 511 in High Grade GliomaTocagen Receives European Medicines Agency Priority Medicines (PRIME) Designation for Toca 511 in High Grade Glioma
finance.yahoo.com - July 25 at 7:43 AM
 Tocagen Inc (NASDAQ:TOCA) Receives Consensus Rating of "Buy" from Brokerages Tocagen Inc (NASDAQ:TOCA) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - July 21 at 8:32 AM

SEC Filings

Tocagen (NASDAQ:TOCA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Tocagen (NASDAQ:TOCA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Tocagen (NASDAQ TOCA) Stock Chart for Monday, February, 19, 2018

Loading chart…

This page was last updated on 2/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.